The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma

Vasudev, Naveen S.; Trigonis, Ioannis; Cairns, David A.; Hall, Geoff; Jackson, David; Broadhead, Timothy; Buxton, John; Hutson, Richard; Nugent, David; Perren, Timothy J.

doi:10.1007/s00404-010-1655-2

Cited by 26 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study we manifested the usefulness of CA 125 in predicting the need of the neoadjuvant chemotherapy in a selected group of patients with advanced ovarian cancer. The area under the curve (AUC) for CA 125 was 0.833 for the entire study group and 0.793 for the serous carcinomas group which is consistent with studies carried out by Vasudev et al [22]. We also showed a statistically significant difference in baseline values of CA 125 among a group of women undergoing the primary surgery followed by the neoadjuvant chemotherapy and between the sensitive and resistant patients to platinum analogues.…”

Section: Discussionsupporting

confidence: 90%

Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer

Chudecka‐Głaz

Cymbaluk‐Płoska

Menkiszak

et al. 2014

Journal of Ovarian Research

View full text Add to dashboard Cite

BackgroundThe most important prognostic factor in the ovarian cancer is optimal cytoreduction. The neoadjuvant chemotherapy, an only optional method of treatment in this case and is still the subject of debate. The object of this study was to evaluate the usefulness of markers: CA 125, HE4, YKL-40 and bcl-2 as well as cathepsin L in predicting optimal cytoreduction and response to chemotherapy.MethodsSera were secured preoperatively. The division into groups was performed retrospectively depending on the method of treatment (surgery vs neoadjuvant chemotherapy) as well as on response to chemotherapy (sensitive vs resistant vs refractory). Comparisons were made between groups, and the diagnostic usefulness of tested proteins was examined.ResultsWe found that statistically significant differences between primary operated patients and patients undergoing neoadjuvant chemotherapy were applicable only to the tumour markers (CA125 1206.79 vs 2432.38, p = 0.000191; HE4 78.87 vs 602.45, p = 0.000004; YKL-40 108.13 vs 203.96, p = 0.003991). Cathepsin-L and Bcl-2 were statistically insignificant. The cut-off point values were determined for the CA 125 (345 mIU/ml), HE4 (218.43 pmol/L) and YKL-40 (140.9 ng/ml). The sensitivity, specificity, PPV and NPV were as follows: CA125 (83.3%; 75%; 80.6%; 78.3%), HE4 (86.6%; 91.3%; 92.9%; 84%) and YKL-40 (75%; 83.3%; 84%; 74.1%).ConclusionAmong the tested proteins the HE4 marker appears to be helpful in forecasting of optimal cytoreduction and possibly also of the prediction of response to platinum analogues used in first-line treatment of ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 90%

Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer

Chudecka‐Głaz

Cymbaluk‐Płoska

Menkiszak

et al. 2014

Journal of Ovarian Research

View full text Add to dashboard Cite

show abstract

“…(Mw < 2000 kDa) and the lack of suitable antibodies for this procedure have posed as a significant analytical limitation that will be addressed in future studies. Even though this is the first report regarding MUC16 expression in bladder cancer, CA125 elevation has been previously observed in the serum of patients with advanced pathological stage in comparison with lowerstage disease, suggesting that this antigen may predict advanced bladder cancer (Margel et al, 2007;Vasudev et al, 2011). Furthermore, abnormal CA125 levels have been associated with unresectable tumours, again reinforcing its association with worse prognosis (Vasudev et al, 2011).…”

Section: Bladder Cancer-targeted Glycoproteomicsmentioning

confidence: 56%

Targeted O‐glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced‐stage bladder tumours

et al. 2017

View full text Add to dashboard Cite

Bladder carcinogenesis and tumour progression is accompanied by profound alterations in protein glycosylation on the cell surface, which may be explored for improving disease management. In a search for prognosis biomarkers and novel therapeutic targets we have screened, using immunohistochemistry, a series of bladder tumours with differing clinicopathology for short‐chain O‐glycans commonly found in glycoproteins of human solid tumours. These included the Tn and T antigens and their sialylated counterparts sialyl‐Tn(STn) and sialyl‐T(ST), which are generally associated with poor prognosis. We have also explored the nature of T antigen sialylation, namely the sialyl‐3‐T(S3T) and sialyl‐6‐T(S6T) sialoforms, based on combinations of enzymatic treatments. We observed a predominance of sialoglycans over neutral glycoforms (Tn and T antigens) in bladder tumours. In particular, the STn antigen was associated with high‐grade disease and muscle invasion, in accordance with our previous observations. The S3T and S6T antigens were detected for the first time in bladder tumours, but not in healthy urothelia, highlighting their cancer‐specific nature. These glycans were also overexpressed in advanced lesions, especially in cases showing muscle invasion. Glycoproteomic analyses of advanced bladder tumours based on enzymatic treatments, Vicia villosa lectin‐affinity chromatography enrichment and nanoLC‐ESI‐MS/MS analysis resulted in the identification of several key cancer‐associated glycoproteins (MUC16, CD44, integrins) carrying altered glycosylation. Of particular interest were MUC16 STn+‐glycoforms, characteristic of ovarian cancers, which were found in a subset of advanced‐stage bladder tumours facing the worst prognosis. In summary, significant alterations in the O‐glycome and O‐glycoproteome of bladder tumours hold promise for the development of novel noninvasive diagnostic tools and targeted therapeutics. Furthermore, abnormal MUC16 glycoforms hold potential as surrogate biomarkers of poor prognosis and unique molecular signatures for designing highly specific targeted therapeutics.

show abstract

“…The CA 125 cut-off value used by Rodriguez et al 16 was substantially greater than that of the present study because Rodriguez et al 16 included a median of 3 courses of NACT, whereas our study included a median of 6 courses. Vasudev et al 18 reported that the regression rate of serum CA 125 levels during NACT had both prognostic and predictive value. However, our results do not support these prior findings, because we observed that the number of NACT courses required for serum CA 125 levels to halve or reduce to <35 U/mL was similar between the optimal/complete and the suboptimal surgery groups.…”

Section: Discussionmentioning

confidence: 99%

Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer

et al. 2017

View full text Add to dashboard Cite

The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma

Abstract: CA-125 regression rate during pre-operative NAC is of independent prognostic value. CA-125 regression rate strongly predicts for optimal cytoreduction.

Cited by 26 publications

References 18 publications

Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer

Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer

Targeted O‐glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced‐stage bladder tumours

Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer

Contact Info

Product

Resources

About